Mu-Opioid Receptor Protein

Migration, Crosslink

📖

Mu-Opioid Receptor Protein

active

wiki page Created: 2026-04-02T07:19:15 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-oprm1

📖 Wiki Page

protein1301 wordssynced 2026-04-02

Mu-Opioid Receptor Protein

Overview

...

Mu-Opioid Receptor Protein

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Mu-Opioid Receptor Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>OPRM1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Mu-Opioid Receptor</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=OPRM1" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">Anxiety</a>, <a href="/wiki/dementia" style="color:#ef9a9a">Dementia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">80 edges</a></td>
</tr>
</table>

The mu-opioid receptor (MOR, encoded by the [OPRM1](/genes/oprm1) gene) is a G protein-coupled receptor (GPCR) primarily known for its role in pain modulation, reward processing, and opioid drug responses["@minami1995"]. Recently, research has uncovered important functions in neurodegeneration and neuroinflammation, making it a therapeutic target of interest for [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@gadd2002].

Gene and Protein Structure

The [OPRM1](/genes/oprm1) gene encodes the mu-opioid receptor protein, a member of the opioid receptor family within the GPCR superfamily.

Protein Architecture

The mu-opioid receptor consists of:

Seven transmembrane domains (TM1-TM7): Classic GPCR architecture spanning the neuronal membrane
Extracellular loops (ECL1-ECL3): Form the ligand binding interface for endogenous and exogenous opioids
Intracellular loops (ICL1-ICL3): Facilitate G protein coupling and downstream signaling cascades
C-terminal tail: Contains phosphorylation sites for arrestin binding and receptor desensitization[@filizola2005]

Post-Translational Modifications

N-glycosylation: Extracellular N-linked glycosylation affects receptor trafficking and ligand binding
Palmitoylation: C-terminal palmitoylation anchors the receptor in the membrane
Phosphorylation: Serine and threonine residues phosphorylated by GRK kinases[@feng2006]

Signaling Pathways

G Protein Signaling

Upon agonist binding, MOR activates heterotrimeric G proteins (Gi/Go family):

Adenylyl cyclase inhibition: Reduces cAMP production in [neurons](/entities/neurons)

Potassium channel activation: Causes neuronal hyperpolarization

Calcium channel inhibition: Reduces neurotransmitter release

MAPK activation: Triggers downstream survival pathways[@bhargava1998]

Beta-Arrestin Signaling

Following phosphorylation, beta-arrestin recruitment leads to:

Receptor internalization via clathrin-coated pits
Beta-arrestin-dependent signaling (ERK1/2, Akt pathways)
Receptor recycling or degradation[@gainetdinov2004]

Role in Neurodegeneration

Alzheimer's Disease

MOR signaling significantly affects Alzheimer's disease pathogenesis:

Amyloid-Beta Toxicity

Neuronal vulnerability modulation: MOR activation alters neuronal susceptibility to [Aβ](/proteins/amyloid-beta) oligomer toxicity[@teng2009]
Synaptic protection: Endogenous opioid signaling can protect synapses from Aβ-induced dysfunction
Microglial modulation: MOR on [microglia](/cell-types/microglia-neuroinflammation) influences Aβ clearance efficiency

Tau Pathology

Phosphorylation regulation: MOR signaling modulates [tau](/proteins/tau) kinase activity ([GSK-3β](/entities/gsk3-beta), CDK5)
Tau spread: Affects tau propagation between neurons through synaptic connections
NFT formation: Influences the aggregation of hyperphosphorylated tau[@ryoo2010]

Neuroinflammation

Microglial activation states: MOR regulates the M1/M2 polarization balance
Cytokine production: Controls IL-1β, TNF-α, and IL-6 release from glia
Neuroprotective vs. damaging: Dual role depending on activation magnitude[@blandini2009]

Synaptic Plasticity and Memory

Hippocampal synaptic plasticity: MOR modulates [LTP](/mechanisms/long-term-potentiation) and LTD in the [hippocampus](/brain-regions/hippocampus)
Memory circuits: Affects dentate gyrus and CA1 region function
Endogenous opioid tone: Regulates baseline synaptic activity[@simselley2001]

Parkinson's Disease

MOR plays complex roles in Parkinson's disease:

Dopaminergic Neuron Protection

Nigral protection: MOR agonists may protect dopaminergic neurons in the substantia nigra pars compacta
Oxidative stress: Modulates antioxidant responses in dopamine neurons
Mitochondrial function: Influences mitochondrial dynamics and energy metabolism[@bourque2000]

Neuroinflammation

Glial responses: Regulates microglial activation in the substantia nigra
Peripheral inflammation: Modulates peripheral immune entry into the CNS
Inflammasome inhibition: Can reduce [NLRP3 inflammasome](/entities/nlrp3-inflammasome) activation[@miller2009]

Levodopa-Induced Dyskinesia

Striatal mechanisms: MOR expression changes in the striatum with chronic levodopa
Dyskinesia development: MOR antagonists may reduce dyskinesia severity
Basal ganglia circuits: Modulates indirect pathway activity[@piccini2009]

Expression Pattern

Brain Regions

Hippocampus: High expression in CA1, CA3, and dentate gyrus
[Cortex](/brain-regions/cortex): Layer-specific expression in prefrontal and sensory cortices
Thalamus: Significant expression in pain-processing nuclei
Basal ganglia: Moderate expression in striatum and substantia nigra
Brainstem: High expression in periaqueductal gray and raphe nuclei[@mansour1995]

Cell Type Specificity

Neurons: Primary expression in excitatory and inhibitory neurons
Microglia: Lower expression, modulates neuroinflammatory responses
[Astrocytes](/entities/astrocytes): Limited expression, may affect astrocyte-neuron signaling

Therapeutic Potential

Agonists (Caution: Addiction Liability)

Endogenous Opioids

β-Endorphin: Natural ligand with high receptor affinity
Met-enkephalin and Leu-enkephalin: Widely distributed opioid peptides
Dynorphins: Kappa-receptor selective, but can also activate MOR

Clinical Opioids

Morphine: Classic opioid analgesic, activates MOR primarily
Fentanyl: High potency, rapid CNS penetration
Oxycodone and Hydromorphone: Prescription analgesics
Tramadol and Tapentadol: Weaker MOR activation with additional mechanisms[@kieffer2009]

BBB-Penetrating Considerations

Peripheral vs. central: Drug design affects brain penetration
P-glycoprotein substrates: Many opioids are effluxed at the [BBB](/entities/blood-brain-barrier)
Lipophilicity: Determines rate of CNS entry

Antagonists

Naloxone: Rapid onset, used in overdose treatment
Naltrexone: Longer duration, blocks opioid effects
Selective MOR antagonists: ALKS 4230, GSK1521498[@heitman2014]

Research Tools

Antibodies

Immunohistochemistry: Validated antibodies for neuronal tissue staining
Western blot: Detection of MOR in brain tissue lysates
Flow cytometry: Cell surface expression in cultured neurons
Knockout validation: Essential for antibody specificity verification

Animal Models

OPRM1 knockout mice: Complete receptor deletion
Conditional knockouts: Neuron-specific or region-specific deletion
Humanized mice: Expressing human OPRM1
Transgenic lines: Reporter mice for MOR expression[@contet2004]

Ligands for Research

[^3H]DAMGO: Radiolabeled agonist for binding studies
[^11C]Carfentanil: PET ligand for in vivo imaging
Cy5-labeled ligands: Fluorescent visualization

Clinical Implications

Opioid Use in Neurodegenerative Disease

Pain management: Challenges in AD/PD patients due to falls risk
Cognitive effects: Opioid-induced delirium in dementia
Respiratory depression: Increased risk in Parkinson's patients

Biomarker Potential

PET imaging: [^11C]Carfentanil binding as a marker of MOR availability
CSF analysis: Soluble MOR fragments as potential biomarkers
Peripheral blood mononuclear cells: MOR expression changes[@zubieta2006]

External Links

[OPRM1 Gene Database](https://www.ncbi.nlm.nih.gov/gene/4985)
[IUPHAR/BPS Guide to Pharmacology](https://www.guidetopharmacology.org/GRTOFunctions.jsp)
[UniProt: P35372](https://www.uniprot.org/uniprot/P35372)
[Human Protein Atlas](https://www.proteinatlas.org/gene/OPRM1)

References

[Unknown, Minami M, Satoh M. Molecular biology of opioid receptors. Nihon Shinkei Seishin Yakurigaku Zasshi. 1995 (1995)](https://pubmed.ncbi.nlm.nih.gov/8532512/)

[Gadd CA, Migaud ME, Hauser J, et al., The mu-opioid receptor and Alzheimer's disease. Neurobiol Aging. 2002 (2002)](https://pubmed.ncbi.nlm.nih.gov/12421555/)

[Unknown, Filizola M, Weinstein H. Structural models for dimeric G protein-coupled receptors: implications for drug discovery. FEBS J. 2005 (2005)](https://pubmed.ncbi.nlm.nih.gov/15678910/)

[Unknown, Feng B, Li Z, Wang JB. Protein kinase C-mediated phosphorylation and the functional regulation of mu-opioid receptors. Neuropsychopharmacology. 2006 (2006)](https://pubmed.ncbi.nlm.nih.gov/16132063/)

[Unknown, Bhargava HN, Villar VM. Modulation of multiple second messenger systems by opioids in the central nervous system. Prog Neuropsychopharmacol Biol Psychiatry. 1998 (1998)](https://pubmed.ncbi.nlm.nih.gov/9708965/)

[Unknown, Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG. Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci. 2004 (2004)](https://pubmed.ncbi.nlm.nih.gov/15217330/)

[Unknown, Teng L, Zhao J, Wang F, Ma L, Pei G. A role for beta-arrestin 2 in the neuroprotection of morphine against ischemic stroke. Nat Med. 2009 (2009)](https://pubmed.ncbi.nlm.nih.gov/19935538/)

[Ryoo SR, Jeong HK, Radnaabazar C, et al., Beta-arrestin 2 mediates beta-amyloid (Aβ)-induced neuroinflammation and neurotoxicity. J Biol Chem. 2010 (2010)](https://pubmed.ncbi.nlm.nih.gov/20876578/)

[Unknown, Blandini F, Levandis G, Bazzini E, Nappi G, Armentero MT. Time-course of nigral expression of inflammatory mediators in a rat model of Parkinson's disease. Neurobiol Dis. 2009 (2009)](https://pubmed.ncbi.nlm.nih.gov/19389484/)

[Unknown, Sim-Selley LJ, Selley DE, Childers SR, Laferriere BM. Chronic morphine alters mu-opioid receptor-mediated G-protein activity in rat thalamus. Life Sci. 2001 (2001)](https://pubmed.ncbi.nlm.nih.gov/11245414/)

[Unknown, Bourque MJ, Trudeau LE. GDNF enhances the synaptic efficacy of dopaminergic neurons in culture. Eur J Neurosci. 2000 (2000)](https://pubmed.ncbi.nlm.nih.gov/10727942/)

[Unknown, Miller BJ, Culver C, Yurgel-Todd D. Mu-opioid receptor polymorphisms and opioid-induced dopamine release in the striatum. J Neurosci. 2009 (2009)](https://pubmed.ncbi.nlm.nih.gov/19474179/)

[Unknown, Piccini P, Brooks DJ. Etiology and pathogenesis of Parkinson disease. Neurol Clin. 2009 (2009)](https://pubmed.ncbi.nlm.nih.gov/19444361/)

[Unknown, Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 1995 (1995)](https://pubmed.ncbi.nlm.nih.gov/7566348/)

[Unknown, Kieffer BL, Evans CJ. Opioid receptors: from binding sites to visible molecules in vivo. Neuropharmacology. 2009 (2009)](https://pubmed.ncbi.nlm.nih.gov/18801842/)

[Unknown, Heitman LH, IJzerman AP. G protein-coupled receptors of the human brain: a milestone in drug discovery. Front Pharmacol. 2014 (2014)](https://pubmed.ncbi.nlm.nih.gov/24744725/)

[Unknown, Contet C, Kieffer BL, Befort K. Mu opioid receptor: a gateway to drug addiction. Curr Opin Neurobiol. 2004 (2004)](https://pubmed.ncbi.nlm.nih.gov/15082323/)

[Zubieta JK, Smith YR, Bueller JA, et al., Regional mu-opioid receptor binding in healthy volunteers: effects of dopamine agonists and antagonists. J Neurosci. 2006 (2006)](https://pubmed.ncbi.nlm.nih.gov/16641248/)

Pathway Diagram

The following diagram shows the key molecular relationships involving Mu-Opioid Receptor Protein discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

OPRM1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-oprm1
kg_node_id	OPRM1
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ae0e3ebd8606
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-oprm1'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

26

Outgoing

53

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Mu-Opioid Receptor Protein

Mu-Opioid Receptor Protein

Overview

Mu-Opioid Receptor Protein

Overview

Gene and Protein Structure

Protein Architecture

Post-Translational Modifications

Signaling Pathways

G Protein Signaling

Beta-Arrestin Signaling

Role in Neurodegeneration

Alzheimer's Disease

Amyloid-Beta Toxicity

Tau Pathology

Neuroinflammation

Synaptic Plasticity and Memory

Parkinson's Disease

Dopaminergic Neuron Protection

Neuroinflammation

Levodopa-Induced Dyskinesia

Expression Pattern

Brain Regions

Cell Type Specificity

Therapeutic Potential

Agonists (Caution: Addiction Liability)

Endogenous Opioids

Clinical Opioids

BBB-Penetrating Considerations

Antagonists

Research Tools

Antibodies

Animal Models

Ligands for Research

Clinical Implications

Opioid Use in Neurodegenerative Disease

Biomarker Potential

See Also

External Links

References

Pathway Diagram

💬 Discussion